Ipsen Launches Employee Savings Plan in 36 Countries at €130.96 per Share
On Friday, the biopharmaceutical group Ipsen announced the launch of an employee savings plan aimed at further involving its employees in the company's development. This initiative, the fifth since 2016, will be extended to 36 countries and will cover employees with at least three months of seniority.
The profit-sharing plan is available to Ipsen employees across 36 countries, including France, the United States, the United Kingdom, Germany, and Japan. Participants must have at least three months of tenure with the group to be eligible. Retirees and pre-retirees who have maintained assets in the group savings plan since their departure are also eligible, although they will not receive employer matching contributions.
Participation Terms and Subscription Price
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The sale will involve existing shares, limited to 1% of the share capital. The subscription price has been set at €130.96 per share, calculated as the average of the opening prices over the twenty trading days preceding the price setting date, reduced by a 20% discount. The subscription period runs from June 3 to June 17, 2026, with settlement-delivery scheduled for July 28, 2026. Subscribed shares will be locked for a period of five years, in accordance with the rules applicable to employee savings plans, except in cases of authorized early release events.
Plan Structure and Employer Contribution
The plan is part of Ipsen's group savings plan (PEG) and Ipsen's international group savings plan. Employees will benefit from an employer matching contribution. Shares can be subscribed in registered form or through a corporate mutual fund (FCPE). This scheme applies to employees with social coverage in the countries where it is implemented and where legal provisions allow.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 190 millions d'euros
Quarterly revenue: 2 190 millions d'euros
Revenue growth: 20,4 %
EBITDA: 733,9 millions d'euros
EBITDA margin: 40,7 %
Net income: 403,1 millions d'euros
Free cash flow: 651,7 millions d'euros
-1 005 millions d'euros
Guidance from the release
Cette dynamique nous permet de relever nos objectifs financiers pour 2026
Risks mentioned
Arrivée potentielle de génériques du lanréotide, concurrençant les ventes de Somatuline
Effet défavorable des devises d'environ 1 % anticipé sur l'exercice 2026
Impact dilutif des acquisitions de Memo Therapeutics AG et de Kartos Therapeutics sur la marge
Opportunities identified
Plusieurs lancements attendus à court terme d'actifs à potentiel de blockbuster dans les trois aires thérapeutiques
Résultats positifs de Phase III de Dysport dans la migraine épisodique et chronique
Résultats positifs de Phase IIIb ELSPIRE d'Iqirvo dans la cholangite biliaire primitive
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.